Clinical experience with the use of a spherical bioactive glass putty for cervical and lumbar interbody fusion

A retrospective clinical case series study was conducted to evaluate the use of a novel, spherical bioactive glass bone graft (BioSphere Putty) as a graft material for cervical and lumbar interbody fusion. Data was collected from a single surgeon using BioSphere Putty along with standardized hardwar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of spine surgery (Hong Kong) 2020-03, Vol.6 (1), p.49-61
Hauptverfasser: Westerlund, L Erik, Borden, Mark
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 61
container_issue 1
container_start_page 49
container_title Journal of spine surgery (Hong Kong)
container_volume 6
creator Westerlund, L Erik
Borden, Mark
description A retrospective clinical case series study was conducted to evaluate the use of a novel, spherical bioactive glass bone graft (BioSphere Putty) as a graft material for cervical and lumbar interbody fusion. Data was collected from a single surgeon using BioSphere Putty along with standardized hardware in anterior cervical decompression and fusion (ACDF), transforaminal lumbar interbody fusion (TLIF), and anterior lumbar interbody fusion (ALIF) surgical procedures. BioSphere Putty was used in combination with cancellous allograft (ACDF and ALIF) or in combination with autograft (TLIF). Clinical outcomes were assessed at 1- and 2-year using radiographic imaging and the visual analog pain scale (VAS). VAS scores at the 1- and 2-year follow-up periods were statistically compared to pre-operative scoring. Successful clinical outcomes were determined by a combination of the presence of a complete radiographic fusion and a decrease in VAS at 1-year and 1- and 2-year follow-up periods. The retrospective review of the patient data identified 248 cases that had either 1- or 1- & 2-year follow-up. This consisted of 115 ACDF procedures and 133 lumbar fusion procedures. Lumbar fusion cases were further sub-grouped with 103 patients undergoing TLIF procedures and 30 patients undergoing ALIF procedures. The global results for the series as a whole showed clinical outcomes comparative to other advanced biologic bone grafts. Radiographically all patients demonstrated fusion (100% fusion rate) and there were no clinical adverse events, infections, or graft-related complications in any of the patients in the series. One-year VAS scores were consistent with historical norms and demonstrated significant decreases in pre-operative pain for both ACDF patients (78% decrease) and lumbar patients (66% decrease TLIF/ALIF) ( test, P
doi_str_mv 10.21037/jss.2020.03.06
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7154357</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32309645</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3086-b87ad1b2362d6e29c3448c8150919adab0c3fcdb7384effd4773e2ff36f553063</originalsourceid><addsrcrecordid>eNpVkF1LwzAUhoMobsxdeyf5A93SnDRpbwQZfsHAGwXvQpIma6RrS9JO9-_dhw69Ogfe57wHHoSuUzKjKQEx_4hxRgklMwIzws_QmLKUJYwDOT_txfsITWP0mjAmWCYyfolGQIEUnGVj1Cxq33ijamy_Ohu8bYzFn76vcF9ZPESLW4cVjl21C_eY9q0yvd9YvKpVjLgb-n6LXRuwsWFzQFRT4npYaxWwb3obdFvuiCH6trlCF07V0U5_5gS9Pdy_Lp6S5cvj8-JumRggOU90LlSZagqcltzSwgBjucnTjBRpoUqliQFnSi0gZ9a5kgkBljoH3GUZEA4TdHvs7Qa9tqWxTR9ULbvg1ypsZau8_J80vpKrdiNFmjHIxK5gfiwwoY0xWHe6TYk82Jc7-3JvXxKQh5c3f1-e-F_X8A0D-YQg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Clinical experience with the use of a spherical bioactive glass putty for cervical and lumbar interbody fusion</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Westerlund, L Erik ; Borden, Mark</creator><creatorcontrib>Westerlund, L Erik ; Borden, Mark</creatorcontrib><description>A retrospective clinical case series study was conducted to evaluate the use of a novel, spherical bioactive glass bone graft (BioSphere Putty) as a graft material for cervical and lumbar interbody fusion. Data was collected from a single surgeon using BioSphere Putty along with standardized hardware in anterior cervical decompression and fusion (ACDF), transforaminal lumbar interbody fusion (TLIF), and anterior lumbar interbody fusion (ALIF) surgical procedures. BioSphere Putty was used in combination with cancellous allograft (ACDF and ALIF) or in combination with autograft (TLIF). Clinical outcomes were assessed at 1- and 2-year using radiographic imaging and the visual analog pain scale (VAS). VAS scores at the 1- and 2-year follow-up periods were statistically compared to pre-operative scoring. Successful clinical outcomes were determined by a combination of the presence of a complete radiographic fusion and a decrease in VAS at 1-year and 1- and 2-year follow-up periods. The retrospective review of the patient data identified 248 cases that had either 1- or 1- &amp; 2-year follow-up. This consisted of 115 ACDF procedures and 133 lumbar fusion procedures. Lumbar fusion cases were further sub-grouped with 103 patients undergoing TLIF procedures and 30 patients undergoing ALIF procedures. The global results for the series as a whole showed clinical outcomes comparative to other advanced biologic bone grafts. Radiographically all patients demonstrated fusion (100% fusion rate) and there were no clinical adverse events, infections, or graft-related complications in any of the patients in the series. One-year VAS scores were consistent with historical norms and demonstrated significant decreases in pre-operative pain for both ACDF patients (78% decrease) and lumbar patients (66% decrease TLIF/ALIF) ( test, P&lt;0.05). By 2 years, VAS scores continued to drop with significant decreases for the ACDF patients (96%), TLIF patients (82%), and ALIF patients (80%) ( test, P&lt;0.05). VAS scores were also assessed for each individual patient. The data showed a VAS score decrease from pre-operative levels in 93% of the ACDF patients and 89% of the lumbar patients. Combined with the 100% radiographic fusion rate in all patients, this resulted in a in a clinical success rate of 93% for the ACDF patients and 89% for the lumbar patients. The results of this clinical case series demonstrated that BioSphere Putty is a clinically effective and versatile synthetic bone graft material in the spine.</description><identifier>ISSN: 2414-469X</identifier><identifier>EISSN: 2414-4630</identifier><identifier>DOI: 10.21037/jss.2020.03.06</identifier><identifier>PMID: 32309645</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Original Study</subject><ispartof>Journal of spine surgery (Hong Kong), 2020-03, Vol.6 (1), p.49-61</ispartof><rights>2020 Journal of Spine Surgery. All rights reserved.</rights><rights>2020 Journal of Spine Surgery. All rights reserved. 2020 Journal of Spine Surgery.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3086-b87ad1b2362d6e29c3448c8150919adab0c3fcdb7384effd4773e2ff36f553063</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154357/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154357/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32309645$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Westerlund, L Erik</creatorcontrib><creatorcontrib>Borden, Mark</creatorcontrib><title>Clinical experience with the use of a spherical bioactive glass putty for cervical and lumbar interbody fusion</title><title>Journal of spine surgery (Hong Kong)</title><addtitle>J Spine Surg</addtitle><description>A retrospective clinical case series study was conducted to evaluate the use of a novel, spherical bioactive glass bone graft (BioSphere Putty) as a graft material for cervical and lumbar interbody fusion. Data was collected from a single surgeon using BioSphere Putty along with standardized hardware in anterior cervical decompression and fusion (ACDF), transforaminal lumbar interbody fusion (TLIF), and anterior lumbar interbody fusion (ALIF) surgical procedures. BioSphere Putty was used in combination with cancellous allograft (ACDF and ALIF) or in combination with autograft (TLIF). Clinical outcomes were assessed at 1- and 2-year using radiographic imaging and the visual analog pain scale (VAS). VAS scores at the 1- and 2-year follow-up periods were statistically compared to pre-operative scoring. Successful clinical outcomes were determined by a combination of the presence of a complete radiographic fusion and a decrease in VAS at 1-year and 1- and 2-year follow-up periods. The retrospective review of the patient data identified 248 cases that had either 1- or 1- &amp; 2-year follow-up. This consisted of 115 ACDF procedures and 133 lumbar fusion procedures. Lumbar fusion cases were further sub-grouped with 103 patients undergoing TLIF procedures and 30 patients undergoing ALIF procedures. The global results for the series as a whole showed clinical outcomes comparative to other advanced biologic bone grafts. Radiographically all patients demonstrated fusion (100% fusion rate) and there were no clinical adverse events, infections, or graft-related complications in any of the patients in the series. One-year VAS scores were consistent with historical norms and demonstrated significant decreases in pre-operative pain for both ACDF patients (78% decrease) and lumbar patients (66% decrease TLIF/ALIF) ( test, P&lt;0.05). By 2 years, VAS scores continued to drop with significant decreases for the ACDF patients (96%), TLIF patients (82%), and ALIF patients (80%) ( test, P&lt;0.05). VAS scores were also assessed for each individual patient. The data showed a VAS score decrease from pre-operative levels in 93% of the ACDF patients and 89% of the lumbar patients. Combined with the 100% radiographic fusion rate in all patients, this resulted in a in a clinical success rate of 93% for the ACDF patients and 89% for the lumbar patients. The results of this clinical case series demonstrated that BioSphere Putty is a clinically effective and versatile synthetic bone graft material in the spine.</description><subject>Original Study</subject><issn>2414-469X</issn><issn>2414-4630</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVkF1LwzAUhoMobsxdeyf5A93SnDRpbwQZfsHAGwXvQpIma6RrS9JO9-_dhw69Ogfe57wHHoSuUzKjKQEx_4hxRgklMwIzws_QmLKUJYwDOT_txfsITWP0mjAmWCYyfolGQIEUnGVj1Cxq33ijamy_Ohu8bYzFn76vcF9ZPESLW4cVjl21C_eY9q0yvd9YvKpVjLgb-n6LXRuwsWFzQFRT4npYaxWwb3obdFvuiCH6trlCF07V0U5_5gS9Pdy_Lp6S5cvj8-JumRggOU90LlSZagqcltzSwgBjucnTjBRpoUqliQFnSi0gZ9a5kgkBljoH3GUZEA4TdHvs7Qa9tqWxTR9ULbvg1ypsZau8_J80vpKrdiNFmjHIxK5gfiwwoY0xWHe6TYk82Jc7-3JvXxKQh5c3f1-e-F_X8A0D-YQg</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Westerlund, L Erik</creator><creator>Borden, Mark</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>202003</creationdate><title>Clinical experience with the use of a spherical bioactive glass putty for cervical and lumbar interbody fusion</title><author>Westerlund, L Erik ; Borden, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3086-b87ad1b2362d6e29c3448c8150919adab0c3fcdb7384effd4773e2ff36f553063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Original Study</topic><toplevel>online_resources</toplevel><creatorcontrib>Westerlund, L Erik</creatorcontrib><creatorcontrib>Borden, Mark</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of spine surgery (Hong Kong)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Westerlund, L Erik</au><au>Borden, Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical experience with the use of a spherical bioactive glass putty for cervical and lumbar interbody fusion</atitle><jtitle>Journal of spine surgery (Hong Kong)</jtitle><addtitle>J Spine Surg</addtitle><date>2020-03</date><risdate>2020</risdate><volume>6</volume><issue>1</issue><spage>49</spage><epage>61</epage><pages>49-61</pages><issn>2414-469X</issn><eissn>2414-4630</eissn><abstract>A retrospective clinical case series study was conducted to evaluate the use of a novel, spherical bioactive glass bone graft (BioSphere Putty) as a graft material for cervical and lumbar interbody fusion. Data was collected from a single surgeon using BioSphere Putty along with standardized hardware in anterior cervical decompression and fusion (ACDF), transforaminal lumbar interbody fusion (TLIF), and anterior lumbar interbody fusion (ALIF) surgical procedures. BioSphere Putty was used in combination with cancellous allograft (ACDF and ALIF) or in combination with autograft (TLIF). Clinical outcomes were assessed at 1- and 2-year using radiographic imaging and the visual analog pain scale (VAS). VAS scores at the 1- and 2-year follow-up periods were statistically compared to pre-operative scoring. Successful clinical outcomes were determined by a combination of the presence of a complete radiographic fusion and a decrease in VAS at 1-year and 1- and 2-year follow-up periods. The retrospective review of the patient data identified 248 cases that had either 1- or 1- &amp; 2-year follow-up. This consisted of 115 ACDF procedures and 133 lumbar fusion procedures. Lumbar fusion cases were further sub-grouped with 103 patients undergoing TLIF procedures and 30 patients undergoing ALIF procedures. The global results for the series as a whole showed clinical outcomes comparative to other advanced biologic bone grafts. Radiographically all patients demonstrated fusion (100% fusion rate) and there were no clinical adverse events, infections, or graft-related complications in any of the patients in the series. One-year VAS scores were consistent with historical norms and demonstrated significant decreases in pre-operative pain for both ACDF patients (78% decrease) and lumbar patients (66% decrease TLIF/ALIF) ( test, P&lt;0.05). By 2 years, VAS scores continued to drop with significant decreases for the ACDF patients (96%), TLIF patients (82%), and ALIF patients (80%) ( test, P&lt;0.05). VAS scores were also assessed for each individual patient. The data showed a VAS score decrease from pre-operative levels in 93% of the ACDF patients and 89% of the lumbar patients. Combined with the 100% radiographic fusion rate in all patients, this resulted in a in a clinical success rate of 93% for the ACDF patients and 89% for the lumbar patients. The results of this clinical case series demonstrated that BioSphere Putty is a clinically effective and versatile synthetic bone graft material in the spine.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>32309645</pmid><doi>10.21037/jss.2020.03.06</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2414-469X
ispartof Journal of spine surgery (Hong Kong), 2020-03, Vol.6 (1), p.49-61
issn 2414-469X
2414-4630
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7154357
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Original Study
title Clinical experience with the use of a spherical bioactive glass putty for cervical and lumbar interbody fusion
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T02%3A31%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20experience%20with%20the%20use%20of%20a%20spherical%20bioactive%20glass%20putty%20for%20cervical%20and%20lumbar%20interbody%20fusion&rft.jtitle=Journal%20of%20spine%20surgery%20(Hong%20Kong)&rft.au=Westerlund,%20L%20Erik&rft.date=2020-03&rft.volume=6&rft.issue=1&rft.spage=49&rft.epage=61&rft.pages=49-61&rft.issn=2414-469X&rft.eissn=2414-4630&rft_id=info:doi/10.21037/jss.2020.03.06&rft_dat=%3Cpubmed_cross%3E32309645%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32309645&rfr_iscdi=true